Inhibrx Biosciences reported positive interim results from its Phase 2 study of INBRX-106 combined with Merck's Keytruda for head and neck cancer, driving the shares higher on Monday. The update is encouraging for the drug candidate and supports the company's clinical development narrative, though it remains an interim readout rather than a definitive trial result.
Inhibrx Biosciences reported positive interim results from its Phase 2 study of INBRX-106 combined with Merck's Keytruda for head and neck cancer, driving the shares higher on Monday. The update is encouraging for the drug candidate and supports the company's clinical development narrative, though it remains an interim readout rather than a definitive trial result.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
